AstraZeneca’s Gout Drug Lesinurad Hobbled By Renal Risk

Lower dose of oral, uric acid transporter inhibitor shows good efficacy in two of three Phase III trials, but renal safety risk appears to limit lesinurad’s potential market – if it gets approved at all.